Alerts will be sent to your verified email
Verify EmailPANACEABIO
Panacea Biotec
|
Bharat Immunological
|
Abbott India
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in USA
|
6.0 . | n/a | n/a |
R&D as a % of Total Sales
|
6.74 % | n/a | 0.02 % |
Financials
|
|||
5 yr Average ROE
|
19.34 % | -29.83 % | 26.29 % |
5yr average Equity Multiplier
|
2.01 | 3.08 | 1.46 |
5yr Average Asset Turnover Ratio
|
0.39 | 0.61 | 1.18 |
5yr Avg Net Profit Margin
|
20.95 % | -18.38 % | 15.35 % |
Price to Book
|
1.01 | 1.69 | 18.18 |
P/E
|
0.0 | 0.0 | 49.35 |
5yr Avg Cash Conversion Cycle
|
-83.17 Days | 206.63 Days | -44.73 Days |
Inventory Days
|
118.8 Days | 125.06 Days | 51.2 Days |
Days Receivable
|
54.62 Days | 61.4 Days | 20.12 Days |
Days Payable
|
284.35 Days | 117.81 Days | 107.05 Days |
5yr Average Interest Coverage Ratio
|
2.91 | -2.32 | 119.35 |
5yr Avg ROCE
|
-10.17 % | -44.64 % | 34.73 % |
5yr Avg Operating Profit Margin
|
-2.87 % | -16.19 % | 22.64 % |
5 yr average Debt to Equity
|
0.41 | 0.71 | 0.0 |
5yr CAGR Net Profit
|
n/a | 23.51 % | 16.09 % |
5yr Average Return on Assets
|
7.46 % | -10.1 % | 18.03 % |
Shareholdings
|
|||
Promoter Holding
|
73.59 % | 59.25 % | 74.99 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
Change in Mutual Fund Holding (3 Yrs)
|
-1.27 % | 0.0 | 4.35 % |
Panacea Biotec
|
Bharat Immunological
|
Abbott India
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
-
|
-
|
Location Wise Break-Up
|
Location Wise Break-Up
|
-
|
Location Wise Break-Up
|
Capex
|
Capex
|
-
|
-
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
-
|
Brand Wise Break-Up
|
Brand Wise Break-Up
|
-
|
Brand Wise Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
-
|